The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The operational efficiencies of using one versus multiple bispecific antibodies for DLBCL and FL
Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, provides insight into her work investigating the operational efficiencies of using one versus multiple bispecific antibodies for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in community centers in the United States, highlighting that adopting one therapy allows for better management and education among staff, as well as cost savings for both practices and patients. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What we were showing in that paper is that, you know, when, let’s say, a community group adopts one therapy, they learn that therapy, right? They’re more educated on that therapy. They’re not having to learn this bispecific from that bispecific. And because they all have, they’re all different. They’re not created the same. Yes, we have to worry about CRS in all of them...
What we were showing in that paper is that, you know, when, let’s say, a community group adopts one therapy, they learn that therapy, right? They’re more educated on that therapy. They’re not having to learn this bispecific from that bispecific. And because they all have, they’re all different. They’re not created the same. Yes, we have to worry about CRS in all of them. That’s not what I’m saying. But, you know, the onset, the severity, all of those things are different. So when you adopt one, then you can learn it, know it well. You can teach your staff, everyone from the infusion team to the pharmacist, to the nurses, you know, every key player that that patient may encounter, it really helps. Plus, cost matters, right? So sometimes when you adopt one medication and put that, say, on formulary, you can also decrease the cost to the patient. You can negotiate contracting better, and it can be more affordable, not only for the practice to purchase the drug to administer, but then, you know, on the patient’s side in terms of what they’re paying. And I have found that, and that’s what that showed, that it’s not only from an efficacy and an efficiency, but it’s also from a cost savings aspect that having one drug is actually beneficial kind of all around compared to having multiple drugs being used.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
